Alcon Completes Acquisition Of Ivantis, Inc., Bringing Hydrus Microstent Into Its Global Surgical Portfolio
Alcon Completes Acquisition Of Ivantis, Inc., Bringing Hydrus Microstent Into Its Global Surgical Portfolio
01/10/22, 6:01 AM
Industry
consumer goods
health care
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the closing of its previously announced acquisition of Ivantis®, developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device designed to lower eye pressure for open-angle glaucoma patients in connection with cataract surgery.*
Company Info
Company info
Alcon Research, LLC is a global leader in eye care, providing innovative products for the treatment of eye conditions. They develop and market a range of surgical and vision care products that enhance patient outcomes. Alcon is focused on improving surgical performance and consumer satisfaction.
Unlock Strategic Intelligence with Fundz
Access real-time funding updates, strategic shifts with FundzWatch™, exclusive Family Offices, and more — helping you close deals and seize opportunities faster.
Trusted by sales, BD, and investment teams at Oracle, HubSpot, Affinity, and more.